IDでもっと便利に新規取得

ログイン


ここから本文です

発表した会社は当然として
Modalisとアプローチが近い銘柄も上がってます

---
NTLA
133.43 +44.60 (+50.21%) Mkt closed
June 28, 2021 4:00 PM EDT


Beam Therapeutics (NASDAQ:BEAM) was up 14% midday Monday on the back of Intellia Therapeutics' (NASDAQ:NTLA) phase 1 data for its therapy to treat a genetic liver disorder.

The excitement should increase attention on Beam's alternative approach, called base editing. While CRISPR-Cas9 has been likened to a pair of genetic scissors, Beam's approach is like a pencil and eraser. Instead of cutting both strands of DNA, Beam is able to chemically change one base letter at a time. Many believe this is an easier approach that leads to fewer accidental insertions or deletions -- known as off-target effects.